Under the agreement, Depomed has granted Watson a co-exclusive right to promote ProQuin XR for the urology and long-term care specialties in the US and its possessions, including Puerto Rico.
Pursuant to the agreement, Depomed will book top-line revenue and Watson will receive a portion of the profits. Watson and Depomed plan to re-launch ProQuin XR in the US urology market by the end of this year. Depomed retains manufacturing and distribution rights and Watson will be responsible for promotion to physicians in urology and long-term care.